chrisvoncsefalvay/vaers-outcomes huggingface dataset:
left arm could not lift it above shoulder; left arm could not lift it above shoulder without severe pain; flu like symptoms the first day; migraine that night (history of migraines; rash on her back, itched really bad; felt like my heart was growing; index finger "split open" by the cuticle; This spontaneous case was reported by a consumer and describes the occurrence of MOBILITY DECREASED (left arm could not lift it above shoulder), MYALGIA (left arm could not lift it above shoulder without severe pain), INFLUENZA LIKE ILLNESS (flu like symptoms the first day), MIGRAINE (migraine that night (history of migraines) and RASH PRURITIC (rash on her back, itched really bad) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 040A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included BUDESONIDE (PULMICORT), GLYCERYL TRINITRATE (NITROLINGUAL), TRAMADOL and FLUTICASONE PROPIONATE (FLUTINASE POLYNEX) for an unknown indication.    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MOBILITY DECREASED (left arm could not lift it above shoulder), MYALGIA (left arm could not lift it above shoulder without severe pain), INFLUENZA LIKE ILLNESS (flu like symptoms the first day), MIGRAINE (migraine that night (history of migraines), RASH PRURITIC (rash on her back, itched really bad), PALPITATIONS (felt like my heart was growing) and LIMB INJURY (index finger "split open" by the cuticle). At the time of the report, MOBILITY DECREASED (left arm could not lift it above shoulder), MYALGIA (left arm could not lift it above shoulder without severe pain), INFLUENZA LIKE ILLNESS (flu like symptoms the first day), MIGRAINE (migraine that night (history of migraines), RASH PRURITIC (rash on her back, itched really bad), PALPITATIONS (felt like my heart was growing) and LIMB INJURY (index finger "split open" by the cuticle) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.
sore arm; little fever; Just a local reaction; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team, Program ID.  A 75-year-old female patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "digestive problems" (unspecified if ongoing), notes: digestive problems. Concomitant medication(s) included: MIRALAX taken for functional gastrointestinal disorder. The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "sore arm"; PYREXIA (non-serious), outcome "unknown", described as "little fever"; LOCAL REACTION (non-serious), outcome "unknown", described as "Just a local reaction". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Reporter stated my wife and I took four regular doses of the Pfizer BioNTech COVID-19 monovalent vaccine. We also had one bivalent booster. We experienced nothing more than a sore arm and a little fever maybe but no rash or no breathing problems. Just a local reaction. We are eligible for the second bivalent booster however, my wife started taking Miralax for digestive problems one or two 17 gram capsules a day and it is pure polyethylene glycol. She might have developed a rash with itching with it, because it started when she started taking it and went away after she quit taking it. We think there is a risk of rash with the Pfizer BioNTech COVID-19 bivalent vaccine, does it contain Polyethylene glycol?.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300180051 same reporter/patient/product/AE, different dose;US-PFIZER INC-202300180052 same reporter/patient/product/AE, different dose;US-PFIZER INC-202300180053 same reporter/patient/product/AE, different dose;US-PFIZER INC-202300180055 same reporter/product/AE, different patient;US-PFIZER INC-202300180056 same reporter/product/AE, different patient;US-PFIZER INC-202300180057 same reporter/product/AE, different patient;US-PFIZER INC-202300180058 same reporter/product/AE, different patient;
Reaction on right deltoid; MENACTRA was given, arm was red, swollen, stated itchy. Skin felt hard. Temperature 97.6, Respirations 20, Oxygen 98%. Treatment: Continue taking KEFLEX, should cover both UTI and arm. Recommend cool compresses and BENADRYL for itching.
itchy rash, 2 inches in diameter, at the site of the injection; soreness at the site of the injection; A spontaneous report was received from a consumer concerning herself, who is a 70-years-old female patient received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events of soreness at the site of the injection, itchy rash, 2 inches in diameter, at the site of the injection.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 25 Jan 2021, prior to the onset of the events the patient received first of two planned doses of mRNA-1273 (lot/batch: 25L20A) through unknown route in the left arm for prophylaxis of COVID-19 infection.  On 26 Jan 2021, the patient experienced the events soreness at the site of the injection,On 3 Feb 2021, the patient experienced the event itchy rash, 2 inches in diameter, at the site of the injection.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.   On 28 Jan 2021 the outcome of event soreness at the site of the injection, at the site of the injection was resolved. The outcome of event itchy rash, 2 inches in diameter was unknown  The reporter did not provide causality for the events; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Patient experienced itching after receiving vaccine, about 10-15 minutes. She was given a ZYRTEC 10 mg. After, she started to scratch her throat and stated that her throat was itchy. 911 was called. They arrived less than five minutes later and checked her vitals, which were within normal range. They asked if she wanted to be transported to the hospital, she declined. She was not having difficulty breathing and her itching had decreased. After 20+ minutes later she was not expereincing any worsening of the itching and said that it was not itching as much and she had no difficulty breathing. Patient did mention blurry vision that had started with the itching, but that was not getting better, but was not worsening.
Left deltoid pain, swelling, redness and pain radiates up into left shoulder and neck and scapula and has pain when lifting left arm 60 degrees flexion or abduction. Also, note, EE developed nausea and vomiting, dry heaves also.
This case was reported by a healthcare professional and described the occurrence of injection arm pain in a female subject of unspecified age who was vaccinated with FLUARIX (GlaxoSmithKline). On 17 September 2010 the subject received a dose of FLUARIX (.5 ml, unknown route, left arm). On 19 September 2010, 2 days after vaccination with FLUARIX, the subject experienced injection arm pain. She also experienced decreased range of motion in the arm where the injection was administered. The subject did not seek medical care until 2 months post vaccination. At the time of reporting the events were improved.
Initial information was received on 12 November 2008 from a health care professional. A "40-50 year old female patient received a left deltoid intramuscular injection of FLUZONE (lot number U2762AA) on 11 November 2008. Shortly after receiving the vaccination, on 11 November 2008, the patient developed right arm warmth and redness from her shoulder to her elbow. She was treated with Prednisone and BENADRYL. The patient's recovery status was not reported. Follow-up information was received 01 December 2008 from a consumer, who is also the patient. The patient had no concurrent illness at the time of vaccination and had recovered from the event. List of Documents held by Sender: None.
just after I received my shot my arm is feeling numb and sore; Inappropriate schedule of vaccine administered; Off label use; received my second shot 3 weeks ago in my left arm and my left arm continues to be numb; This is a spontaneous report from a contactable consumer or other non hcp (patient).   A 61-years-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot Number: EW0221), via an unspecified route of administration, administered in Arm Left on 03Jun2021 (at age of 61-year-old), as dose 2, single for covid-19 immunization. Medical history included asthma from an unknown date and unknown if ongoing. Concomitant medication included fluticasone propionate, salmeterol xinafoate (ADVAIR) taken for an unspecified indication, start and stop date were not reported. Patient previously took BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot Number: EP6775), via an unspecified route of administration, administered in Arm Left on 28Feb2021, as dose 1, single for covid-19 immunisation and no reactions were reported. On 03Jun2021, just after he received shot, the patient experienced arm was feeling numb and sore, inappropriate schedule of vaccine administered, off label use. Therapeutic measures were taken as a result of events included advil. The outcome of the events was unknown.   Follow-up attempts were possible. Further information was expected.
Patient received a Hep B, was suppose to be Hep A, Hep B series was completed.
Patient received the Japanese Encephalitis Vaccine and started to don her blouse.  Pt stated that she needed to sit down and began to slouch over.  I caught the patient and gently leaned her back on the exam table and lifted her legs and placed on the exam table  foot rest.  I was speaking to the patient until she regained consciousness.  Patient was pale and sweating.  Once patient regained consciousness, the patient stayed laying down and was given a cold pack.  Patient stayed laying down for roughly five minutes and then was able to sit up and had the exam table placed into the seated position.  patient stated her fingers were tingling. Patient was given a glass of water and crackers and felt better within moments. Patient stated she did not eat breakfast and did not drink much water but had a Monster energy drink.  I sat with the patient for about 20 minutes after the episode and ensured she felt well enough to stand and walk.  I consulted a medical provider to ensure nothing else was required. Patient felt well enough to leave and did not wish to be seen by a provider was escorted to her car by another team member.
pt woke up with a heat rash with white bumps on face after 2 days getting vaccinated. pt got rash again 10 days after vaccination.
Information has been received via VAERS concerning a 1.4 year old female who on 12-FEB-1999 was vaccinated SC in the left arm with a first dose of measles virus vaccine live (Enders-Edmonston) (+) mumps virus vaccine live (Jeryl Lynn) (+) rubella virus vaccine live (Wistar RA 27/3) (lot # 626120/1647H). Concomitant vaccination included a fourth dose of Hib conj vaccine (CRM197) (HIBTITER) (lot # 360753A) given IM in the right leg. On 16-FEB-1999 the patient experienced a fever x 8 days to 104.8, a maculopapular rash, conjunctivitis, gingivitis, positive strep culture and no CNS problems. The patient did not meet full criteria for Kawasaki's but an echo was done anyway and was normal. The patient was treated with antibiotics and antipyretics. The patient recovered and had no residual problems. The patient's skin was tested for MMR and was negative. No further information is available.
2 hours after vaccine I experienced facial numbness on the right side. I immediately messaged my doctor and she explained it was probably a bells palsy reaction but it should clear itself. After 5 days the tingly sensation, numbness and weeping eye finally went away.
REDNESS AND SWELLING ON SITE; LETHARGIC; LOW GRADE FEVER; HEADACHE; This spontaneous report received from a patient concerned a 53 year old female. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 043A21A, and batch number: 043A21A expiry: UNKNOWN) dose was not reported, administered on 02-APR-2021 for prophylactic vaccination at left arm.. No concomitant medications were reported. On 03-APR-2021, the subject experienced redness and swelling on site. On 03-APR-2021, the subject experienced lethargic. On 03-APR-2021, the subject experienced low grade fever. On 03-APR-2021, the subject experienced headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from headache, and had not recovered from redness and swelling on site, low grade fever, and lethargic. This report was non-serious.
Pt had very bad nausea all night after shot, severe muscle pain, severe bone pain, lower limbs pain. This all happened within 24-48 hours after shot.
Intentional misuse in product use duration; Appetite lost; FELT ACHY; Diarrhea; Upset stomach; Unevaluable event; This spontaneous case was reported by a physician and describes the occurrence of INTENTIONAL PRODUCT MISUSE (Intentional misuse in product use duration), DECREASED APPETITE (Appetite lost), PAIN (FELT ACHY), DIARRHOEA (Diarrhea) and ABDOMINAL DISCOMFORT (Upset stomach) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and ADALIMUMAB (HUMIRA) (Subcutaneous) 1 dosage form. On an unknown date, the patient experienced INTENTIONAL PRODUCT MISUSE (Intentional misuse in product use duration), DECREASED APPETITE (Appetite lost), PAIN (FELT ACHY), DIARRHOEA (Diarrhea), ABDOMINAL DISCOMFORT (Upset stomach) and UNEVALUABLE EVENT (Unevaluable event). At the time of the report, INTENTIONAL PRODUCT MISUSE (Intentional misuse in product use duration), DECREASED APPETITE (Appetite lost), PAIN (FELT ACHY), DIARRHOEA (Diarrhea), ABDOMINAL DISCOMFORT (Upset stomach) and UNEVALUABLE EVENT (Unevaluable event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment information was provided by the reporter. No concomitant information was provided by the reporter. There was no reported medical history. It was unknown if the patient was enrolled in Covid-19 vaccine trial On 25th June, 2021 the event of stopped Humira for eight weeks to take the Covid-19 vaccine was amended.
Community health worker came to this RN, after several attempts made to check patient was unsuccessful.  It was subsequently realized she 14yrs/10mos. and should not have been vaccinated.  Upon hearing this, this RN realized that she had personally administered this vaccine. RN immediately notified Dr who felt that in the next few months this age group would be included in the vaccine, and that someone, "with more authority than he" should determine if patient is to get her 2nd dose as this was not scheduled. This RN spoke directly to patient's mother, asking, "what prompted her to bring patient realizing that she was only 14 y'o'?"  Mom stated, "I received a note from the school telling me that it was ok so I brought her".  This RN shared that we must get our information from the scientist/researchers/health care experts and government on when this age would be included and that as a part of the team, she should have waited until she heard this on a news station that she could trust to which she agreed. This RN shared that patient will surely benefit from some degree of immunity for this 1st dose, and responded that she is not clear if she will need 2 or just one dose when her time comes per the moms question. RN met w/ clinic manager to discuss how processes not people failed to work in this instance and that we would develop a process to ensure that this does not occur again.  Met w/ CHW who signed her  in and shared the same content r/t creating a new process.  Again, shared w/ AAC Director as well.
p/ pt recv vax pt devel vesicular rash w/approx 20-30 lesions, several impetiginous lesions. pt seen by MD who noticed all vesicles had crusted over
First 2 doses caused fatigue (which lasted about 24 hrs) and tenderness near the injection site and swelling /tenderness in armpit (which lasted about 4 days) After booster shot - within a few hours of vaccination injection site was red, hot, swollen, hard and painful to move the arm. 3 days later redness has spread but swelling is dissipating and pain is just tenderness.   The morning after injection the armpit of the same arm was also tender and swollen but in a small knot rather than the whole armpit.
Fever 103, nausea, vomiting, dizziness, generalized body aches.
This spontaneous report was received from a registered nurse regarding a 16 year old patient of unknown gender. The patient's medical history, concurrent conditions, drug allergies or concomitant therapies were not reported. On 09-MAR-2017, the patient was inadvertently vaccinated with a dose of PROQUAD injection (dose and route were not reported) lot number: M042499; expiration date: 17-APR-2017, for prophylaxis. According to the reporter, receiving a dose of PROQUAD was not indicated as the patient had measles, mumps, rubella and varicella prevention in the medical history. No adverse effects were reported. Additional information has been requested.
Experiencing a menstrual period for the first time in five years. I have a Nexplanon implant and do not experience menstruation typically since receiving the implant. I had light spotting in April 2021 and a full heavy period in May 2021.
Systemic: Headache-Severe, Systemic: Other- Death 8 days after receiving the vaccine-Severe
pt recvd vax;  marked, swelling, redness & induration of entire upper arm w/ fever up to 103 x 72 hrs;
48 hours after receiving DTAP pt developed increased erythema & warmth at injection site. No increased pain no fever, no cough or SOB. Child appeared nontoxic, nontender to palpation.
I started my period on time but have had unbearably painful cramps. I don?t typically have cramps on my period but I?ve had to take ibuprofen all day.
Client reported feeling lightheaded following vaccination. Client offered water and ice pack placed behind neck. Vital signs initiated. Observation time extended. Left site once issues resolved and they stayed they were ?feeling better?
30 y/o female with hx of SVT (on propranolol), presented to the ER on 1-12-22 for CP with radiation to left shoulder/jaw/neck x 7 hours (woke her from sleep at 0200 that day). No SOB, dizziness, N/V, diaphoresis. CXR normal. Bedside ECHO organized cardiac motion, no pericardial effusion. Troponin 0.469>0.9170 (012-0.034 ng/mL). EKG diffuse T wave inversion consistent with peri-myocarditis. Transferred to hospital for formal ECHO and cardiology evaluation. There her CT angiogram was negative for PE. ECHO with hypokinesis of the apex which lead to suspicion for Takotsubo cardiomyopathy. EF 57%.PT HAS SINCE STILL HAD SYMPTOMS, BUT IMPROVING OVER THE LAST MONTH.  LAST ECHO SHOWED NORMAL EF AND NO WMA.
Rash and itch around the spot of vaccination.   No treatment. By April 8, the rash has gone but the itch remain as of April 12.
This spontaneous report as received from a licensed practical nurse referring to a 4-year-old patient of unreported gender. The patient's relevant medical history and concomitant medications were not provided. On 29-DEC-2021 the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) 0.5ml (lot number reported as U019286, expiration date 15-DEC-2022; vaccination scheme frequency, route of administration were not reported) for prophylaxis. On 28-DEC-2021, Improperly stored the administered dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (product storage error) as follows: minus 10.6 (-10.6) degree Celsius (C) for 30 minutes. The product has no previous excursions.
Large saddle pulmonary embolism.  No DVT.  Patient stable, hospitalized.  Form competed upon admission, unknown duration of hospitalization at this time
Mother noted aches and pain on 10/5/12 and vasculitis rash lower extremities 10/6/12 where clothes bind, ankle, knee, inner thighs.
Coughing (dry mostly), mild fever (~100-102), runny nose for 2 days, exhaustion and muscle aches
12/29 vaccination  wife had runny nose on the 1st.  1/3/2021 runny nose, fatigue.  1/4/2021  COVID; neg 1/8/2021 - found out on  1/12th COVID; Pos 1/14 cleared from isolation cleared for 2nd vaccine; 1/15th
This spontaneous report was received from a pharmacist refers to a male patient of unknown age. The patient's medical history included chickenpox. On 10-NOV-2014, the patient was vaccinated with ZOSTAVAX (strength, dose, route, lot# were not reported). Concomitant therapy was not reported. On an unknown date approximately in November 2014 (reported as within 2 to 3 days) the patient over 30 spots. The patient was seen by the physician who diagnosed him with chicken pox. The patient had been quarantined for the next week. Patient sought medical attention by visiting physician. No Product Quality Complaint (PQC) was involved. The outcome of chicken pox was reported as not recovered/not resolved. Causality assessment was not provided by the reporter. This is one of the two reports from the same reporter. This case was linked to MARRS # 1411USA012528 (patient wife case). Additional information has been requested.
About 19 hours after receiving the flu shot, I experienced severe reactions that I have never received from the flu shot in 3 decades of receiving them. The reactions were akin to the severe reactions that I receive from the covid vaccine, which led me to wonder if the pharmacist mistakenly gave me the covid vaccine. I had extreme body aches, exhaustion, weakness, high fever (101). Use of Tylenol only slightly reduced my fever. The symptoms finally broke about 14 hours after they started.
1)Nausea, vomiting, Diarrhea. 2)Some hallucinotion 3)Lethargic
01/31/2021 sore red hard shot area. Then was ok til 02/8/2021 saw the red hard shot area again and itchy with tiny bumps in red area.
Patient reported slight lightheadedness, blurred vision and SOB.  Patient had low HR of 45, but states she usually runs low. Patient was monitored and placed on O2, and later discharged as she reported improvement in symptoms.